- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Damora Therapeutics Inc (DMRA)
Assess today's live Damora Therapeutics Inc (DMRA) share price, performance and insights using our live NASDAQ: DMRA stock exchange data.
Analyse the historical data and Damora Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on Damora Therapeutics share price buy/sell indicators using real-time data (or discuss the Damora Therapeutics (DMRA) stock price today with other investors in the Damora Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ DMRA share price (ISIN: US36322Q2066) to enhance your trading decisions with our free investment tools and resources.
What Is the Damora Therapeutics Inc Share Price Today?
The Damora Therapeutics share price today is 24.210.
What Is the Stock Symbol for Damora Therapeutics Inc
The stock symbol (or 'ticker') for Damora Therapeutics Inc is "DMRA."
What Stock Exchange Does Damora Therapeutics Inc Trade On?
Damora Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Damora Therapeutics Inc a Good Stock to Buy?
Determining whether Damora Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Damora Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on Damora Therapeutics share price buy/sell indicators using real-time data (or discuss the Damora Therapeutics (DMRA) stock price today with other investors in the Damora Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ DMRA share price (ISIN: US36322Q2066) to enhance your trading decisions with our free investment tools and resources.
What Is the Damora Therapeutics Inc Share Price Today?
The Damora Therapeutics share price today is 24.210.
What Is the Stock Symbol for Damora Therapeutics Inc
The stock symbol (or 'ticker') for Damora Therapeutics Inc is "DMRA."
What Stock Exchange Does Damora Therapeutics Inc Trade On?
Damora Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Damora Therapeutics Inc a Good Stock to Buy?
Determining whether Damora Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
24.210
+0.170(+0.71%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
24.000
24.310
52 wk Range
2.450
38.325
DMRA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
24.00024.310
52 wk Range
2.45038.325
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DMRA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
44.500
Upside
+83.81%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Galecto Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Galecto Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 44.500
(+83.81% Upside)
Earnings
Latest Release
12/05/2026
EPS / Forecast
-0.81 / -0.32
Revenue / Forecast
-- / --
Compare DMRA to Peers and Sector
Metrics to compare | DMRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDMRAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.2x | −4.5x | −0.5x | |
PEG Ratio | 0.10 | 0.00 | 0.00 | |
Price/Book | 3.8x | 2.4x | 2.6x | |
Price / LTM Sales | - | 2.5x | 3.1x | |
Upside (Analyst Target) | 86.0% | 188.6% | 55.1% | |
Fair Value Upside | Unlock | 17.5% | 7.2% | Unlock |
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Damora Therapeutics (NASDAQ: DMRA) Share Price Today?
The Damora Therapeutics stock price today is 24.210 USD.
What Stock Exchange Does Damora Therapeutics (DMRA) Trade On?
Damora Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Damora Therapeutics?
The stock symbol (also called a 'ticker') for Damora Therapeutics is "DMRA."
What Is the Current Damora Therapeutics Market Capitalisation?
As of today, Damora Therapeutics (NASDAQ: DMRA) market cap is 1.450B USD.
What Is Damora Therapeutics's (DMRA) Earnings Per Share (TTM)?
The Damora Therapeutics EPS is currently -24.470 (Trailing Twelve Months).
Is DMRA a Buy or Sell From a Technical Analyst Perspective?
Based on today's Damora Therapeutics moving averages and other technical indicators, the daily buy/sell signal for DMRA stock is Strong Sell.
How Many Times Has Damora Therapeutics Stock Split?
Damora Therapeutics has split 1 times. (See the DMRA stock split history page for full effective split date and price information.)
How Many Employees Does Damora Therapeutics Have?
Damora Therapeutics has 7 employees, based on their latest Companies House report.
What is the current trading status of Damora Therapeutics (NASDAQ: DMRA)?
As of 20/05/2026, Damora Therapeutics (DMRA) is trading at a share price of 24.210 USD, with a previous close of 24.040 USD. The stock has fluctuated within a day range of 24.000 USD to 24.310 USD, while its 52-week range spans from 2.450 USD to 38.325 USD.
What Is Damora Therapeutics (DMRA) Price Target According to Analysts?
The average 12-month price target for Damora Therapeutics is 44.500 USD, with a high estimate of 51 USD and a low estimate of 40 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +83.81% Upside potential.
What Is the DMRA Premarket Price?
DMRA's last pre-market stock price is 24.400 USD. The pre-market share volume is 13,420.000, and the stock has decreased by 0.360, or 1.500%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.